Reader sentiment, not investment advice. One vote per visitor; click again to change it.
EXEL last changed hands at $58.28 (down 0.22%). At $14.44B, Exelixis is ranked #694 by size among the 800 stocks on BeStock.
The stock's 52-week band runs $33.76 to $61.14, and the latest print sits 4.7% under the top end of it.
Buyers are paying 18.3 times trailing earnings. The median for its industry group is 33.2.
6 analysts follow the stock and the average call is "buy". The mean target, $53.67, sits 7.9% under where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 3 factors below, ranked against the 800 U.S. stocks BeStock covers.
Cheaper on P/E than most of BeStock’s coverage scores higher.
Trading closer to its 52-week high than most peers scores higher.
6 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
EXEL is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2020-07-06, the strategy has returned 1524.8% (321.7% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $53.67, 7.9% below today’s price, with a consensus rating of Buy.
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Quote as of Oct 1, 2026 12:20 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 800 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Set against the peer table: at 18.3x earnings, EXEL looks about mid-pack against the market, and trades 45% below the 33.2x median among Biotechnology names. The two comparisons do not always agree.
$58.28 is the latest print for EXEL, a move of -0.22% against yesterday's close of $58.41. Today's low and high so far: $57.76 and $59.28.
Equity value comes to $14.44B at the current price. By that measure it is number 694 of the 800 names in our coverage.
Buyers pay 18.3 times the last twelve months of profit (EPS $2.78).
The year's floor is $33.76 and the ceiling $61.14. Shares are 4.7% away from that ceiling.
Our data shows no dividend paid by Exelixis over the trailing twelve months.
Of 6 analysts, 50% say buy, 33% hold and 17% sell. Price targets average $53.67, with the most cautious at $41.00 and the most optimistic at $64.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on EXEL.